Advertisement

Current Pediatrics Reports

, Volume 6, Issue 1, pp 26–29 | Cite as

Cannabidiol in Pediatric Epilepsy

  • Dallas ArmstrongEmail author
  • Eric Marsh
Neurology (D Stephenson, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Neurology

Abstract

Purpose of Review

To summarize current understanding of the role of endocannabinoids as well as exogenous cannabinoids such as tetrahydrocannabiniol and cannabidiol in the functions of the body, including the brain, and to explore the role of cannabidiol in the treatment of pediatric epilepsy.

Recent Findings

Previously, the evidence supporting the role of cannabidiol in the treatment of epilepsy was largely anecdotal. In 2017, two randomized, placebo-controlled, clinical trials suggested that cannabidiol may be effective in the treatment of epilepsy, though conclusions about both seizure reduction and adverse effects are clouded by the large number of patients taking concomitant anti-seizure medications (such as valproic acid and clobazam) whose serum levels are often increased with the administration of cannabidiol.

Summary

Cannabidiol has been well-tolerated in pediatric patients and may be an effective treatment for medically intractable epilepsy. Future studies that control for concomitant administration of clobazam and/or valproic acid are necessary.

Keywords

Cannabidiol CBD Cannabis Epilepsy 

Notes

Compliance with Ethical Standards

Conflict of Interest

Dallas Armstrong declares no conflicts of interest. Eric Marsh reports grants and non-financial support from Greenwich Pharma, grants and non-financial support from Zogenix Pharma, personal fees from Easai Pharma, personal fees from Cydan Pharma, non-financial support from Rett Syndrome Research Trust, grants from NIH, and grants from State of PA, outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Website: National and State Estimates of the Numbers of Adults and Children with Active Epilepsy—United States, 2015, published Aug 2017. Accessed 11/1/2017. https://www.cdc.gov/mmwr/volumes/66/wr/mm6631a1.htm.
  2. 2.
    Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE commission on classification and terminology, 2005–2009. Epilepsia. 2010;51(4):676–85.  https://doi.org/10.1111/j.1528-1167.2010.02522.x.CrossRefPubMedGoogle Scholar
  3. 3.
    Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. 1990;87(5):1932–6.  https://doi.org/10.1073/pnas.87.5.1932.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology. 2004;47:345–58.  https://doi.org/10.1016/j.neuropharm.2004.07.030.CrossRefPubMedGoogle Scholar
  5. 5.
    Koo MK, Hoon-Chul K. Could cannabidiol be a treatment option for intractable childhood and adolescent epilepsy? J Epilepsy Res. 2017;7(1):16–20.  https://doi.org/10.14581/jer.17003.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Hampson RE, Deadwyler SA. Cannabinoids, hippocampal function and memory. Life Sci. 1999;65(6–7):715–23.  https://doi.org/10.1016/S0024-3205(99)00294-5.CrossRefPubMedGoogle Scholar
  7. 7.
    Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev. 2003;83(3):1017–66.  https://doi.org/10.1152/physrev.00004.2003.CrossRefPubMedGoogle Scholar
  8. 8.
    Basu S, Ray A, Dittel BN. Cannabinoid receptor 2 is critical for the homing and retention of marginal zone B lineage cells and for efficient T-independent immune responses. J Immunol. 2011;187(11):5720–32.  https://doi.org/10.4049/jimmunol.1102195.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes. 2006;30(Suppl 1):S13–8.  https://doi.org/10.1038/sj.ijo.0803272.CrossRefGoogle Scholar
  10. 10.
    Hill A, Hill T, Whalley B. The development of cannabinoid based therapies for epilepsy. In: Murillo-Rodriguez E, Onaivi ES, Darmani NA, Wagner E, editors. Endocannabinoids: molecular pharmacological, behavioral, and clinical features. Oak Park: Bentham Science; 2013. p. 164–204.Google Scholar
  11. 11.
    Jones NA, Hill AJ, Smith I, Bevan SA, Williams CM, Whalley BJ, et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther. 2010;332(2):569–77.  https://doi.org/10.1124/jpet.109.159145.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199–215.  https://doi.org/10.1038/sj.bjp.0707442.CrossRefPubMedGoogle Scholar
  13. 13.
    • Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trail. Lancet. 2016;15:270–8.  https://doi.org/10.1016/S1474-4422(15)00379-8. This is one of the larger open-label trials to date. CrossRefPubMedGoogle Scholar
  14. 14.
    Press CA, Knupp KG, Chapman KE. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav. 2015;45:49–52.  https://doi.org/10.1016/j.yebeh.2015.02.043.CrossRefPubMedGoogle Scholar
  15. 15.
    US Food and Drug Administreation. Warning letters and test results. 2015. http://www.fda.gov/NewsEvents/PublicHealthFocus/ucm435591.htm. Accessed Oct 31, 2017.
  16. 16.
    Vandrey R, Raber J, Raber M, Douglass B, Miller C, Bonn-Miller M. Dose and label accuracy in edible medical cannabis products. JAMA. 2015;313(24):2491–2.  https://doi.org/10.1001/jama.2015.6613.CrossRefPubMedGoogle Scholar
  17. 17.
    Bonn-Miller M, Loflin M, Thomas B, Marcu J, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online. JAMA. 2017;318(17):1708–9.  https://doi.org/10.1001/jama.2017.11909.CrossRefPubMedGoogle Scholar
  18. 18.
    •• Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011–20. This is one of two randomized, controlled trials evaluating CBD for epilepsy. CrossRefPubMedGoogle Scholar
  19. 19.
    •• Thiele EA, Marsh ED, French JA, et al. Cannabidiol significantly reduces drop seizure frequency in Lennox-GAstaut syndrome: results of a multi-center, randomized, double-blind, placebo-controlled trial. Lancet. 2017. This is one of two randomized, controlled trials evaluating CBD for epilepsy. Google Scholar
  20. 20.
    Ames FR, Cridland S. Anticonvulsant effect of cannabidiol. S Afr Med J. 1985;69:14.Google Scholar
  21. 21.
    Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246–51.  https://doi.org/10.1111/epi.13060.CrossRefPubMedGoogle Scholar
  22. 22.
    Gaston TE, Bebin EM, Cutter GR, Lie Y, Szaflarski JP. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58(9):1586–92.  https://doi.org/10.1111/epi.13852.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Child NeurologyChildren’s Hospital of PhiladelphiaPhiladelphiaUSA

Personalised recommendations